Perrigo Cash Flow Statement
NYSE: PRGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Perrigo free cash flow
In fiscal 2025, Perrigo generated $238.5 million of operating cash flow and spent $93.4 million on capital expenditures. That left free cash flow of $145.1 million, a free-cash-flow margin of 3.4% of revenue. Free cash flow was down 40.7% from the prior year's $244.6 million.
Perrigo returned $159.3 million to shareholders through dividends, equal to 110% of free cash flow. Free cash flow covered dividend payments 0.9 times.
Summary generated from market data by MetaCap's automated system. Methodology
Perrigo cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -1.43B | -171.80M | -12.70M | -140.60M | -68.90M | -162.60M | 146.10M | 131.00M | 119.60M | -4.01B |
| Net Income growth (YoY) | — | — | — | — | — | -211.29% | +11.53% | +9.53% | — | -3048.42% |
| Depreciation & Amortization | 337.50M | 325.90M | 359.50M | 338.60M | 312.20M | 384.80M | 396.50M | 423.60M | 444.80M | 457.00M |
| Stock-Based Compensation | 54.60M | 64.40M | 68.80M | 54.90M | 60.10M | 58.50M | 52.20M | 37.70M | 43.80M | 23.00M |
| Change in Working Capital | -101.10M | -74.70M | -58.50M | 20.00M | -295.40M | -69.20M | -313.50M | -19.40M | -103.90M | -101.50M |
| Operating Cash Flow | 238.50M | 362.90M | 405.50M | 307.30M | 156.30M | 636.20M | 387.80M | 593.00M | 698.90M | 654.90M |
| Capital Expenditures | -93.40M | -118.30M | -101.70M | -96.40M | -152.10M | -170.40M | -137.70M | -102.60M | -88.60M | -106.20M |
| Investing Cash Flow | -75.40M | 78.80M | -77.50M | -1.96B | 1.28B | -187.80M | -596.10M | -126.80M | 2.34B | -175.00M |
| Dividends Paid | -159.30M | -152.50M | -149.70M | -142.40M | -129.60M | -123.90M | -112.40M | -104.90M | -91.10M | -83.20M |
| Share Repurchases | — | — | — | 0 | 0 | -164.20M | 0 | -400.00M | -191.50M | 0 |
| Debt Issued | 0 | 1.09B | 295.10M | 1.59B | 0 | 743.80M | 600.00M | 431.00M | 0 | 1.19B |
| Debt Repaid | -34.80M | -1.53B | -325.30M | -970.60M | -30.60M | -590.00M | -476.00M | -482.50M | -2.61B | -559.20M |
| Financing Cash Flow | -220.50M | -611.00M | -187.20M | 421.60M | -178.70M | -181.10M | 1.80M | -571.90M | -3.00B | -268.70M |
| Net Change in Cash | -24.90M | -192.50M | 150.60M | -1.28B | 1.24B | 287.20M | -196.80M | -127.60M | 56.40M | 204.50M |
| Free Cash Flow | 145.10M | 244.60M | 303.80M | 210.90M | 4.20M | 465.80M | 250.10M | 490.40M | 610.30M | 548.70M |
This table shows 10 annual periods of Perrigo's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PRGO's reporting calendar. What is a cash flow statement?